(4-isopropyl-phenyl)-acetic acid amide | 116435-80-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (4-isopropyl-phenyl)-acetic acid amide
• 英文别名: (4-Isopropyl-phenyl)-essigsaeure-amid；2-(4-Propan-2-ylphenyl)acetamide
• CAS: 116435-80-4
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: ZSDRUCLBZVXODT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-异丙基苯乙腈 在 盐酸 作用下， 生成 (4-isopropyl-phenyl)-acetic acid amide
  参考文献：
  名称：

  Rhizoctonia disease of potatoes (Rhizoctonia solani): Fungicidal efficacy and cultivar susceptibility

  摘要：

  Rhizoctonia stem canker and black scurf is an economically important disease of potatoes in Alberta and around the world. It reduces the quality and yield of potatoes and has become an important impediment for export of seed potatoes, especially to Mexico. Seed treatment using fungicides, presently registered in Canada, are not effective in controlling the disease to growers' satisfaction. Field experiments conducted to evaluate the efficacy of various fungicides showed that captan (Captan), iprodione (Rovral), mancozeb (Tuberseal), and fludioxonil (Maxim) provide effective control of the disease. Of these fungicides, fludioxonil consistently provided superior protection. Based on the results of this study, Maxim was registered in 2000 for control of this disease in Canada. Potato cultivars/hreeding selections showed a range of susceptibility reactions to R. solani but none of these was completely resistant to the disease. The information on comparative susceptibility of potato cultivars will help the growers make informed decisions regarding the management of this disease. Of six plant species (Beta vulgaris, Brassica compestris, Hordeum vulgare, Pisum sativum, Triticum aestivum, Zea mays) most commonly used in rotation with potatoes in Alberta, none was infected by potato isolates of R. solani. The results suggested that use of these plant species as rotation crops with potatoes in Alberta will help in reducing the development of rhizoctonia disease in potatoes.

  DOI：

  10.1007/bf02881518

文献信息

• [EN] ANTIBACTERIAL BENZOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES BENZOIQUES ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004018428A1

  公开（公告）日：2004-03-04

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗菌剂和使用这些剂进行哺乳动物的消毒、卫生、防腐、消毒和治疗感染的方法。
• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及Formula I的烷基喹啉和烷基喹噁啉化合物： 其中R1、R2、R3、B、Z、G、Q和X如本文所定义，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受试者中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，以及所述化合物的用途为预防或治疗受试者的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明还涉及包括本发明化合物的药物组合物，以及治疗癌症和其他细胞增殖紊乱等疾病的方法。
• [EN] AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE UTILES POUR LE TRAITEMENT DE MALADIES MÉTABOLIQUES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2012098033A1

  公开（公告）日：2012-07-26

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病，举例不限。
• [EN] ANTIFUNGAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIFONGIQUES
  申请人：UNIV LEUVEN KATH

  公开号：WO2011072345A1

  公开（公告）日：2011-06-23

  The present invention relates to a series of novel compounds which have been shown to possess antifungal activity. The invention therefore relates to the new compounds, methods for their preparation, pharmaceutical compositions comprising them and to the compounds for use as a medicament, more in particular antifungal medicament.

  本发明涉及一系列已被证明具有抗真菌活性的新化合物。因此，该发明涉及新化合物、其制备方法、包含它们的药物组合物以及用作药物，尤其是抗真菌药物的化合物。
• [EN] TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS TRICYCLIQUES DE PYRAZOLOPYRIDINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2010135014A1

  公开（公告）日：2010-11-25

  The present invention relates to compounds useful as inhibitors of P13K, particularly of P13Kgamma. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of several diseases, such as cancer and autoimmune diseases.

  本发明涉及作为P13K抑制剂的化合物，特别是P13Kγ。该发明还提供包含所述化合物的药学上可接受的组合物，以及使用这些组合物治疗多种疾病的方法，如癌症和自身免疫疾病。